Q3 2025 Performance Highlights - Total net revenue increased by 2% to $314 million compared to $307 million in Q3 2024[11] - SUBLOCADE net revenue increased by 15% to $219 million compared to $191 million in Q3 2024[11] - Adjusted EBITDA increased by 14% to $120 million compared to $105 million in Q3 2024[11] Financial Guidance Update - Total net revenue guidance raised to $1180 million - $1220 million, a 1% increase compared to previous guidance[34] - SUBLOCADE net revenue guidance raised to $825 million - $845 million, a 10% increase compared to previous guidance[34] - Adjusted EBITDA guidance raised to $400 million - $420 million, a 15% increase compared to previous guidance[34] Strategic Initiatives - The company is executing Phase I of the Indivior Action Agenda, focusing on generating momentum[13, 42] - Expect at least $150 million in Non-GAAP operating expense savings in 2026[17, 35] - U S SUBLOCADE YTD net revenue growth of 7% to $561 million compared to $524 million[17]

Group 1 - Indivior PLC will participate in the Stifel 2025 Healthcare Conference on November 13, 2025, with CEO Joe Ciaffoni and CFO Ryan Preblick hosting meetings and a fireside discussion [1] - The fireside discussion will be publicly available via a live webcast [1] - Indivior focuses on developing medicines for opioid use disorder (OUD) and aims to transform OUD into a recognized chronic disease [1] Group 2 - Indivior is set to report its third quarter 2025 financial results on October 30, 2025, at 7:00 a.m. [2] - The company has published results from a clinical trial in JAMA Network Open, supporting rapid SUBLOCADE® induction to improve retention in OUD treatment [3]

Core Viewpoint - Indivior PLC plans to change its domicile from the U.K. to the U.S. by establishing a new parent company, Indivior Pharmaceuticals, Inc. (IPI), to leverage the benefits of its U.S. stock listing [1][2]. Group 1: Redomiciliation Process - The redomiciliation will be executed through a U.K. court-sanctioned scheme of arrangement, requiring shareholder approval [2][3]. - Upon approval, Indivior PLC will become a wholly owned subsidiary of IPI, with IPI's common stock listed on Nasdaq under the symbol INDV [2][3]. - Shareholders will receive one IPI share for each Indivior PLC share held, with Indivior PLC shares cancelled at the time of exchange [2]. Group 2: Timeline and Voting - A formal vote by Indivior PLC shareholders is necessary, requiring a majority in number and 75% in value of shares voted [3]. - Key dates include: - Mid November 2025: Issuance of shareholder circular and notice of extraordinary general meeting (EGM) - Early December 2025: EGM held in London - Late January 2026: Effective date of the scheme and trading of IPI shares on Nasdaq begins [7]. Group 3: Strategic Benefits - The change aims to expand Indivior's presence in U.S. capital markets and increase potential U.S. equity indexation [6]. - It will simplify corporate governance and reduce complexity, positioning Indivior as a U.S.-based treatment innovator [6]. - The move is expected to enhance collaboration with public health leaders on advancing SUBLOCADE® for opioid use disorder [6].